Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, is among the most common diseases affecting aging men, but the underlying molecular features remain poorly understood, and therapeutic options are limited. Here we employ a comprehensive molecular investigation of BPH, including genomic, transcriptomic and epigenetic profiling. We find no evidence of neoplastic features in BPH: no evidence of driver genomic alterations, including low coding mutation rates, mutational signatures consistent with aging tissues, minimal copy number alterations, and no genomic rearrangements. At the epigenetic level, global hypermethylation is the dominant process. Integrating transcriptional and methylation signatures identifies two BPH subgroups with distinct clinical features and signaling pathways, validated in two independent cohorts. Finally, mTOR inhibitors emerge as a potential subtype-specific therapeutic option, and men exposed to mTOR inhibitors show a significant decrease in prostate size. We conclude that BPH consists of distinct molecular subgroups, with potential for subtype-specific precision therapy.

Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes / Liu, Deli; Shoag, Jonathan E.; Poliak, Daniel; Goueli, Ramy S.; Ravikumar, Vaishali; Redmond, David; Vosoughi, Aram; Fontugne, Jacqueline; Pan, Heng; Lee, Daniel; Thomas, Domonique; Salari, Keyan; Wang, Zongwei; Romanel, Alessandro; Te, Alexis; Lee, Richard; Chughtai, Bilal; Olumi, Aria F.; Mosquera, Juan Miguel; Demichelis, Francesca; Elemento, Olivier; Rubin, Mark A.; Sboner, Andrea; Barbieri, Christopher E.. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - ELETTRONICO. - 11:1(2020), pp. 19871-19879. [10.1038/s41467-020-15913-6]

Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes

Romanel, Alessandro;Demichelis, Francesca;Sboner, Andrea;
2020

Abstract

Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, is among the most common diseases affecting aging men, but the underlying molecular features remain poorly understood, and therapeutic options are limited. Here we employ a comprehensive molecular investigation of BPH, including genomic, transcriptomic and epigenetic profiling. We find no evidence of neoplastic features in BPH: no evidence of driver genomic alterations, including low coding mutation rates, mutational signatures consistent with aging tissues, minimal copy number alterations, and no genomic rearrangements. At the epigenetic level, global hypermethylation is the dominant process. Integrating transcriptional and methylation signatures identifies two BPH subgroups with distinct clinical features and signaling pathways, validated in two independent cohorts. Finally, mTOR inhibitors emerge as a potential subtype-specific therapeutic option, and men exposed to mTOR inhibitors show a significant decrease in prostate size. We conclude that BPH consists of distinct molecular subgroups, with potential for subtype-specific precision therapy.
1
Liu, Deli; Shoag, Jonathan E.; Poliak, Daniel; Goueli, Ramy S.; Ravikumar, Vaishali; Redmond, David; Vosoughi, Aram; Fontugne, Jacqueline; Pan, Heng; Lee, Daniel; Thomas, Domonique; Salari, Keyan; Wang, Zongwei; Romanel, Alessandro; Te, Alexis; Lee, Richard; Chughtai, Bilal; Olumi, Aria F.; Mosquera, Juan Miguel; Demichelis, Francesca; Elemento, Olivier; Rubin, Mark A.; Sboner, Andrea; Barbieri, Christopher E.
Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes / Liu, Deli; Shoag, Jonathan E.; Poliak, Daniel; Goueli, Ramy S.; Ravikumar, Vaishali; Redmond, David; Vosoughi, Aram; Fontugne, Jacqueline; Pan, Heng; Lee, Daniel; Thomas, Domonique; Salari, Keyan; Wang, Zongwei; Romanel, Alessandro; Te, Alexis; Lee, Richard; Chughtai, Bilal; Olumi, Aria F.; Mosquera, Juan Miguel; Demichelis, Francesca; Elemento, Olivier; Rubin, Mark A.; Sboner, Andrea; Barbieri, Christopher E.. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - ELETTRONICO. - 11:1(2020), pp. 19871-19879. [10.1038/s41467-020-15913-6]
File in questo prodotto:
File Dimensione Formato  
s41467-020-15913-6.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 2.8 MB
Formato Adobe PDF
2.8 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11572/280258
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 13
social impact